The therapeutic potential of targeting this axis is demonstrated by the efficacy of BER inhibitors in suppressing tumor growth in vivo, establishing APE1-G4 targeting as a promising anti-resistance strategy. This evidence concerns the gene APEX1 and neoplasm.